Array BioPharma Inc.'s Phase III trial planned for this summer in recurrent low-grade serous ovarian cancer (LGSOC) with its Novartis AG-partnered MEK inhibitor is one of a handful of late-stage studies expected to roll out this year.
Concert Pharmaceuticals Inc.'s third deal in just over two years with its deuterium-modifying platform brought Celgene Corp. aboard for a single project at first – an up-front payment along with more than $300 million possible in milestone rewards – but with the potential for more compounds that would bring similar financial terms.
An existing partner with two other deals jumped aboard Ambrx Inc.'s site-specific, antibody drug conjugate (ADC) bandwagon, as Bristol-Myers Squibb Co. provided $15 million up front plus funding for discovery and research, as well as milestone payments of that could total $97 million per oncology product emerging from the collaboration.
Abide Therapeutics Inc.'s potential $430 million deal with Merck & Co. Inc. is focusing on Type II diabetes by way of small molecules that take aim at members of the serine hydrolase enzyme family.
Risk-shy investors who'd rather bank on approved products make up Capital Royalty L.P.'s second fund, $805 million worth of private equity for betting in increments of between $20 million and $200 million, though the amounts could go higher.
The possibility of an initial public offering (IPO) – noted in December, when Regado Biosciences Inc. collected $51 million in a Series E financing intended to help fund Phase III trials – moved closer to reality, as the firm filed a registration statement to trade on Wall Street.
Radius Health Inc.'s new equity cash of $43 million will go toward further work with its anabolic bone builder BA058, in Phase III trials as an injectable therapy and Phase II as a "short-wear" patch.
CHICAGO – Navigating the patent landscape in developing countries is hard enough, and made even trickier by such moves as the one made earlier this month by El Salvador, which passed a law that cut prices by at least 30 percent for more than 6,000 medicines, and as much as 60 percent for the most common therapies.
CHICAGO – Officials from the China Food and Drug Administration (CFDA) stammered through a question-and-answer period in which the audience sought the agency's definition of an "innovative" drug, its stance on orphan therapies and its policy with regard to biosimilars, during the first day of the BIO 2013 International Convention here.
